

# Biomarkers of Venous Thromboembolism Recurrence After Discontinuation of Low Molecular Weight Heparin Treatment for Cancer-Associated Thrombosis (HISPALIS-Study)

Remedios Otero, Aurora Solier-López, Verónica Sánchez-López, Julia Oto, Elena Arellano, Samira Marín, Luis Jara-Palomares, Teresa Elías, María Isabel Asencio, Isabel Blasco-Esquivias, María Rodríguez de la Borbolla, José María Sánchez-Díaz, Macarena Real-Domínguez, Emilio García-Cabrera, Francisco Javier Rodríguez-Martorell, and Pilar Medina

**Table S1.** Clinical Characteristics of the patients treated with LMWH beyond 6 months.

	Stopped anticoagulant therapy (Included patients) N = 166	Not stopped anticoagulant therapy (Excluded patients) N = 211
Sex male, N (%)	89 (53.6)	121 (57.4)
Age (y), median (IQR)	64 (17)	63.6 (16)
Weight (Kg), median (IQR)	71 (20)	75.0 (20)
Cancer location, N (%)		
Cerebral	3 (1.8)	5 (2.4)
Digestive	35 (21.1)	59 (28)
Hematologic	28 (16.9)	13 (6)
Breast and Ovarian	30 (18.1)	33 (15.5)
Lung	19 (11.4)	40 (19)
Urinary	26 (15.6)	33 (15.5)
Other	25 (15.1)	28 (13)
VTE, N (%)		
DVT	89 (53.6)	113 (53.4)
PE	47 (28.3)	51 (24)
DTV + PE	18 (10.8)	33 (15.5)
Atypical VTE	12 (7.2)	14 (6.8)
Incidental VTE	50 (30)	89 (42.2)
PT g. 20210G>A, N (%)	6 (5.0)	5 (11.0)
FV Leiden, N (%)	10 (6.0)	5 (11.0)
Anti-phospholipid antibody, N (%)	2 (1.7)	1 (2.2)
ECOG status $\geq 2$	16 (9.6)	38 (18.1)
Active metastasis, N (%)	65 (39.2)	147 (70)
Chemotherapy, N (%)	56 (33.7)	125 (59.4)
CV Catheter, N (%)	12 (7.2)	29 (13.7)
Months of anticoagulant treatment, median (IQR)	11 (11)	38 (18)
DVT resolution, N (%)	72/107 (67.2)	45/145 (31)
PE resolution, N (%)	53/65 (81.5)	58/84 (69)

Prothrombin gene mutation g.20210G>A, FV Leiden and anti-phospholipid antibody analysis was performed in 120 patients in the stopped anticoagulant therapy group and in 45 patients in the not stopped anticoagulant therapy group. LMWH: low-molecular-weight heparin; IQR: interquartile range; VTE: venous thromboembolism; DVT: deep vein thrombosis; PE: pulmonary embolism; PT: prothrombin; CV: central venous.